Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Ulf Landmesser MD, FESC

    Ulf Landmesser MD, FESC

    Professor of Cardiology

    Medical Director, Department of Cardiology

    Charite University Hospital

    Berlin, Germany


    Related Videos

    Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial? Video

    Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

    Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition? Video

    Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

    With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations? Video

    With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

    In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor? Video

    In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

    Can you discuss the ESC Guidelines for LDL-C targets and the recent AHA Guidelines designating a target threshold of 70 mg/DL? Is this low enough? What is your recommendation for PCSK9 inhibition in the high-risk ACS patient who has undergone PCI? Video

    Can you discuss the ESC Guidelines for LDL-C targets and the recent AHA Guidelines designating a target threshold of 70 mg/DL? Is this low enough? What is your recommendation for PCSK9 inhibition in the high-risk ACS patient who has undergone PCI?

    What has been your clinical experience with respect to the comparative toleration of statins vs. PCSK9 inhibitors? Video

    What has been your clinical experience with respect to the comparative toleration of statins vs. PCSK9 inhibitors?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED